Results 31 to 40 of about 1,725 (146)

Meeting the Unmet Need in the Management of MDR Gram‐Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Critical Care Research and Practice, Volume 2022, Issue 1, 2022., 2022
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad‐spectrum antibacterial agents developed for the treatment of difficult‐to‐treat infections caused by multidrug‐resistant Gram‐positive bacteria, especially methicillin‐resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well
Yatin Mehta, K. C. Mishra, Yashesh Paliwal, Pradeep Rangappa, Sharmili Sinha, Sandeep Bhapkar, Guowei Tu   +6 more
wiley   +1 more source

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates

Antibiotics, 2022
For decades, the spread of multidrug-resistant (MDR) Acinetobacter baumannii has been rampant in critically ill, hospitalized patients. Traditional antibiotic therapies against this pathogen have been failing, leading to rising concerns over management ...
Manas S. Deolankar, Rachel A. Carr, Rebecca Fliorent, Sean Roh, Henry Fraimow, Valerie J. Carabetta   +5 more
doaj   +1 more source

Omadacycline Efficacy against Streptococcus Agalactiae Isolated in China: Correlation between Resistance and Virulence Gene and Biofilm Formation

Computational Intelligence and Neuroscience, Volume 2022, Issue 1, 2022., 2022
This study aimed to evaluate the activity, resistance, clonality of MIC distribution, and the correlation between virulence and resistance genes and biofilm formation of omadacycline (OMC) in clinics for Streptococcus agalactiae isolates from China. 162 isolates were collected retrospectively in China. The S.
Guiqiu Li, Ying Wei, Yan Guo, Hui Gong, Jie Lian, Guangjian Xu, Bing Bai, Zhijian Yu, Qiwen Deng, Arpit Bhardwaj   +9 more
wiley   +1 more source

Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective

Antibiotics, 2021
Introduction: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated Clostridioides difficile infection (HCA-CDI). The validated Davis risk score (DRS) indicates that patients with a DRS
Thomas Lodise, Mauricio Rodriguez, Surya Chitra, Kelly Wright, Nimish Patel   +4 more
doaj   +1 more source

Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia

International Journal of Infectious Diseases, 2021
Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR)
Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg, Anita F. Das, Marla Curran, Amy Manley, Evan Tzanis, Paul C. McGovern   +9 more
doaj   +1 more source

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in Microbiology, 2020
Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee, Yi-Tzu Lee, Hsing-Yu Chen, Ya-Sung Yang, Yu-Ching Chou, Tein-Yao Chang, Wei-Jane Hsu, I-Chieh Lin, ACTION Study Group, Jun-Ren Sun   +9 more
doaj   +1 more source

Empiric treatment approach for the management of post-operative incisional infections with omadacycline

Foot & Ankle Surgery: Techniques, Reports & Cases, 2023
: Background: Surgical wound dehiscence (SWD) is one of the most common complications of surgical incision sites after foot surgeries because of blood flow and circulation issues that may occur in the foot. Such SWD complications can potentially lead to
Philip Wrotslavsky
doaj   +1 more source

Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease

mSphere
Treatment outcomes for Mycobacteroides abscessus (Mab, also known as Mycobacterium abscessus) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy.
Elisa H. Ignatius, Binayak Rimal, Chandra M. Panthi, Daniel C. Belz, Christopher K. Lippincott, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane   +7 more
doaj   +1 more source

Case Report: Omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient

Frontiers in Cellular and Infection Microbiology, 2023
Omadacycline is a novel tetracycline antibiotic that exhibits good in vitro antibacterial activity against atypical pathogens such as Mycoplasma pneumoniae. It is approved for the treatment of adults with community-acquired bacterial pneumonia.
Limin Xu, Changquan Fang
doaj   +1 more source

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards ...
Michael A. Pfaller, Michael D. Huband, Dee Shortridge, Robert K. Flamm   +3 more
doaj   +1 more source